Reuters logo
BRIEF-Aclaris Therapeutics completes phase 1 clinical trial of ati-50001
May 5, 2017 / 12:21 PM / 7 months ago

BRIEF-Aclaris Therapeutics completes phase 1 clinical trial of ati-50001

May 5 (Reuters) - Aclaris Therapeutics Inc:

* Aclaris Therapeutics completes phase 1 clinical trial of ati-50001 for the treatment of alopecia universalis and alopecia totalis

* In trial, treatment with ati-50001 capsules was well tolerated, with a safety profile similar to placebo

* No clinically significant laboratory abnormalities were observed

* Aclaris Therapeutics - data consistent with results from earlier phase 1 clinical trial conducted by rigel pharma in which study drug was well tolerated at all doses

* Aclaris Therapeutics - plans to initiate phase 2 dose ranging trial with ati-50001 for treatment of alopecia totalis, alopecia universalis in second half of 2017

* Aclaris Therapeutics - plans to submit an investigational new drug application (ind) for ati-50002 for treatment of patchy alopecia areata in mid-2017

* Plans to initiate phase 2 trial of ati-50002 for treatment of vitiligo in second half of 2017

* Aclaris Therapeutics Inc - plans to initiate a phase 2 dose ranging trial of ati-50002 for treatment of patchy alopecia areata in second half of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below